These data indicated that CIR potentiated the tumor immune microenvironment by inducing CD8+ TILs to be reprogrammed into more functionally competent cells, which was responsible for better tumor control in prostate cancer‐bearing mice treated by CIR. The gene discussed is CD8A; the disease is prostate carcinoma.